Commercial products

YUTREPIA™ (treprostinil) inhalation powder

YUTREPIA is an FDA-approved, inhaled dry-powder formulation of treprostinil indicated for the treatment of pulmonary arterial hypertension (PAH). Delivered through a convenient, low-resistance, palm-sized device, YUTREPIA was designed using Liquidia’s PRINT® technology. PRINT enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation.


See Prescribing Information

Report an Adverse Event or Product Complaint

To report SUSPECTED ADVERSE REACTIONS, contact Liquidia Technologies, Inc. at 1-888-393-LQDA (5732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Treprostinil Injection

Liquidia promotes the appropriate use of Sandoz® Treprostinil Injection in the United States in conjunction with its commercial partner, Sandoz, Inc. (Sandoz), which holds the Abbreviated New Drug Application (ANDA) with the FDA.

Treprostinil Injection is a fully substitutable AP-rated generic formulation of Remodulin® (treprostinil) Injection. Treprostinil Injection is therapeutically equivalent to Remodulin.

Remodulin® is a registered trademark of United Therapeutics Corporation.


See Prescribing Information

Report an Adverse Event or Product Complaint

Patient & family resources

As part of our work to support patients and their families, we are proud to connect patients with organizations that work to advance research and advocacy for people living with PAH.

Patient Voices

Patients and caregivers are the experts on living with pulmonary hypertension (PH). Through Patient VOICES, we invite you to share your experience and help shape our work alongside the PH community by telling your story, joining an advisory board, speaking at events or with media, or reviewing patient materials.